Scienture Holdings, Inc. — Filing Summary
Issuer identification: The supplied filing is Trxade Group, Inc.’s Form 10-K, not a filing under the name Scienture Holdings, Inc. The filing reports the fiscal year ended December 31, 2019 and was signed March 30, 2020.
Business context and reporting period
Trxade operates a web-based pharmaceutical marketplace connecting independent pharmacies and suppliers, and also owns a specialty pharmacy and a licensed pharmaceutical wholesaler. The marketplace charges suppliers transaction fees; most revenue in 2019 and 2018 came from the platform. The company was expanding into telehealth through Bonum Health hubs, planned to begin operating in 2020.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $7.436 million | $3.832 million |
| Gross profit | $4.871 million | $3.383 million |
| Gross margin | 65.5% | 88.3% |
| Operating income (loss) | $125,224 | $(87,616) |
| Net income (loss) | $(284,428) | $9,038 |
| Cash from operating activities | $141,775 | $273,386 |
- Revenue grew 94.1%, reflecting greater generic-product activity on the marketplace, a full year of Community Specialty Pharmacy versus roughly three months in 2018, and wholesale activity at Integra.
- Cost of sales rose to $2.566 million from $449,049, outpacing revenue growth and reducing gross margin. Operating expenses totaled $4.746 million and included a $368,520 write-off of acquired software assets.
- Net loss reflected, among other items, a $250,000 loss on the SyncHealth investment, a $178,500 debt-extinguishment loss, and $53,227 of interest expense. SyncHealth was terminated effective January 31, 2020, and the investment was fully written off.
- At year-end, cash was $2.872 million, working capital was $3.282 million, current assets were $3.803 million, and current liabilities were $520,816. Short-term debt was zero; related-party long-term notes were $225,000, due in 2021. Lease liabilities totaled $772,811, including $87,350 current.
- Cash increased by $2.002 million, largely because of $2.455 million in 2019 stock-sale proceeds. Investing used $332,252 and financing provided $2.193 million. Two customers each represented more than 10% of revenue (10.3% and 10.8%).
Material changes, outlook and notable items
- In February 2020, the company completed a public offering, including the underwriters’ overallotment, and reported approximately $5.3 million in net proceeds for working capital, general corporate purposes, and possible acquisitions. It also completed a 1-for-6 reverse stock split and began Nasdaq Capital Market trading as MEDS.
- Management estimated 2020 operating expenses and working-capital requirements at approximately $5 million, primarily general and administrative costs. It said year-end cash and expected operating resources were sufficient for current operations, while noting future expansion or acquisitions could require additional capital. This is an expense estimate, not revenue or earnings guidance.
- The Bonum Health asset acquisition included 41,667 shares issued and up to 108,334 additional milestone shares, plus a funding obligation of up to $600,000 subject to milestones. The company subsequently found the acquired assets unusable and wrote off approximately $369,000. Hub operations were planned for 2020; adoption, provider availability, regulatory compliance and execution were uncertain.
- The filing warned that early-2020 coronavirus disruptions could affect pharmaceutical supply, outsourced technology work, employee productivity and 2020 results; the scale and duration were not estimable at filing.
- A lawsuit against the company’s subsidiary and CEO sought $425,000 in compensatory and $1.275 million in punitive damages. The company disputed the claims; it said it could not estimate probable or reasonably possible losses.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2019, citing material weaknesses in financial reporting systems, segregation of duties, written policies and period-end reporting controls. Remediation was ongoing. The auditor gave an unqualified opinion on the financial statements but did not audit or opine on internal-control effectiveness.
Important facts for investors to verify
- Confirm the issuer identity: the supplied document names Trxade Group, Inc., while the request names Scienture Holdings, Inc.
- Reconcile revenue presentation: audited statements report 2019 revenue of $7,436,264, while one MD&A sentence gives $7,346,264. Also reconcile the differing operating-expense classifications in the MD&A table and audited statement.
- Assess the sustainability and cash conversion of marketplace growth, the decline in gross margin, customer concentration, and the profitability of pharmacy and wholesale operations.
- Track remediation of material control weaknesses, the Bonum hub rollout and funding commitments, and the outcome or updated loss assessment for the litigation.
- Evaluate post-year-end financing, dilution and potential milestone shares, as well as the effect of pandemic-related supply and operating disruptions.